GIP Protein, Mouse, Recombinant (His)

The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 418.00
500 μg	5 days	$ 1,670.00
1 mg	5 days	$ 2,800.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 418.00

500 μg

5 days

$ 1,670.00

1 mg

5 days

$ 2,800.00

Description

Species	Mouse
Expression System	HEK293
Tag	C-His
Accession Number	P48756
Synonyms	GIP, Incretin
Construction	Recombinant Mouse GIP Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Glu22-Gln85.[Accession \|P48756]
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	The protein has a predicted MW of 8.7 kDa. Due to glycosylation, the protein migrates to 13-18 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.